Allergic diseases have become a major public health problem in affluent societies. 1 Reduced microbial exposure, both prenatally and postnatally, has been proposed to underlie the increase in allergy development. [2] [3] [4] [5] The gut microbiota, which hosts a complex bacterial community, is quantitatively the most important source of microbial stimulation and might provide a primary signal for appropriate immune development. 4 The gut microbiota differs in composition and diversity during the first months of life in children who later do or do not have allergic disease, 2, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] although no specific microbes with consistently harmful or allergy-protective roles have yet been identified. Also, we observed that differences in the gut microbiota diversity during infancy between healthy children and children with allergies were mainly related to asthma and not allergic rhinoconjunctivitis (ARC) development. 16 Early establishment of a diverse gut microbiota, with repeated exposure to new bacterial antigens, might be more important than the distribution of specific microbial species in shaping a normal immune mucosal and systemic maturation. 4 A reduced mucosal barrier function might increase the risk for allergy development, 1 and IgA is the primary mediator of humoral mucosal immunity. 18 IgA is the most abundantly produced antibody in human subjects, with the highest amount of secretion in the intestinal tract. 18, 19 Secretory IgA (SIgA) has a crucial role in the gut through its binding to bacterial antigens, thus preventing their direct interaction with the host through immune exclusion and maintaining mucosal homeostasis. 18, 20 SIgA can also limit overgrowth of select species, thus stimulating diversity. 18, 21 Therefore this antibody represents a key host mechanism in regulation of the commensal community, and innate receptor signaling in T cells seems to decide the specificity of IgA to constrain the composition of the intestinal bacteria, ensuring a benign symbiotic relationship. 19 However, in contrast to IgG and IgM levels, generation of this anti-inflammatory antibody is limited during early infancy, and delayed development of mucosal IgA production, for instance in the absence of breast-feeding, might lead to infectious disease in young infants. 22, 23 Studies and clinical reports suggest that SIgA that originates from the mother's breast milk is important for immune regulation and protection against bacterial, viral, and parasitic infections in suckling infants. [23] [24] [25] [26] [27] Although total SIgA levels in saliva and fecal samples have been investigated in children with allergy before, little is known about the identities of the bacterial taxa targeted by IgA in the infant gut and what role mucosal immune responses to the gut microbiota play in childhood allergy development. However, earlier studies have shown that low levels of salivary and intestinal SIgA are associated with an increased risk for allergic manifestations during early life. [28] [29] [30] Recent advances in flow cytometry 31 and next-generation sequencing 32 now allow study of the complex interactions between human antibodies and microbiota. In this study we used flow cytometry-based cell sorting and barcoded 16S rDNA 454-pyrosequencing to characterize the dominant gut bacteria, coated or noncoated with IgA, and determined total SIgA levels and bacterial load in stool samples collected during the first year of life in infants who either had allergic manifestations or stayed healthy up to 7 years of age.
METHODS
For detailed methods, experimental protocols and statistical analyses, see the Methods section in this article's Online Repository at www.jacionline.org.
Study design
The infants included in this study were part of a larger randomized doubleblind trial in southeastern Sweden between 2001 and 2003 evaluating the potential allergy prevention effect of probiotic Lactobacillus reuteri ATCC 55730 until 2 33 and 7 34 years of age. The recruited children had a family history of allergic disease (> _1 family members with eczema, asthma, gastrointestinal allergy, allergic urticaria, or ARC), and more detailed inclusion and exclusion criteria are explained in the study of Abrahamsson et al. 33 Among the 188 infants completing the original study, infant stool samples collected at 1 and 12 months of life in 20 children with allergy (see Table E1 in this article's Online Repository at www.jacionline.org) and 28 children staying healthy up to 7 years of age (see Table E2 in this article's Online Repository at www.jacionline.org) were randomly selected for this study (Fig 1) . Ten of the allergic children had asthma. Other allergic diseases included eczema (n 5 9 at 7 years of age and n 5 17 at 2 years of age; no infants had eczema before 1 month of age), ARC (n 5 10), and allergic urticaria (n 5 1), with symptoms defined as described in detail previously. 33, 34 The samples were immediately frozen at 2208C after collection and later stored at 2708C until use.
There were no differences regarding potential confounders, such as sex, mode of delivery, birth order, maternal atopy, breast-feeding, antibiotics, and probiotic supplementation, between the infants who did or did not have allergic manifestations (Table I ). All included infants were exclusively breast-fed for at least 1 month, and no infant received antibiotics before 1 month of age. 12 The Regional Ethics Committee for Human Research at Link€ oping University approved the study. Informed consent was obtained from both parents before inclusion. The study is registered at ClinicalTrials.gov (ID NCT01285830). 32 
Sample labeling and flow cytometry protocol

DNA extraction
DNA from sorted fecal bacteria, both IgA1 and IgA2, was isolated by using the MasterPure complete DNA and RNA Purification Kit (Epicentre Biotechnologies, Madison, Wis), according to the manufacturer's instructions, with a previous glass bead beating (0.17 mm in diameter) and an additional enzymatic lysis step with lysozyme (20 mg/mL, 378C, 30 minutes; Thermomixer comfort, Eppendorf, Hamburg, Germany).
16S rDNA gene amplification and sequencing
DNA from 192 samples in total was used for PCR amplification and pyrosequencing to describe the bacterial composition of the sorted populations. A region of approximately 650 bp of the 16S rDNA gene was amplified by using universal bacterial degenerate primers, 35 which encompass the hypervariable regions V3 to V5 of the gene. A secondary amplification was performed with the purified PCR product as a template. 36 
Sequence processing and taxonomic classification
The resulting 16S rDNA read ends were trimmed in 10-bp sliding windows, with an average value of 20 or greater, by using the Galaxy tool, 37 and only reads of longer than 250 bp were considered. The sequences were assigned to each sample by using the 8-bp barcode through the Ribosomal Database Project (RDP) pipeline, version 11.3, 38 and chimeric sequences were filtered out with UCHIME. 39 Taxonomic assignment was performed by using the RDP classifier, 38 in which the reads were assigned a phylum, class, family, and genus, and phylogenetic ranks were allocated when scores exceeded the 0.8 confidence threshold. Shannon indices, based on a randomly selected 700 reads per sample, was used to estimate the samples' diversity on the gene and phylum level.
For analyzing IgA coating patterns, the threshold used for including the genera was 1% or greater relative abundance in either the IgA1 or IgA2 fractions. The abundance proportions of a given genera were used to calculate the ratio between the IgA1 and IgA2 fractions, providing the IgA index. 40 Thus this score was based on proportional representation for every given genus within the IgA1 (positive IgA index values) and IgA2 fractions (negative IgA index values), reflecting the degree of mucosal immune responsiveness to the microbiota. Linear discriminant analysis effect size (LEfSe) 41 was then used for high-dimensional biomarker discovery, comparing the IgA indices between healthy infants and infants with allergic manifestations. Furthermore, principal components analysis (PCA) was performed with the R software ade4 package. 42 Bacterial load analysis with quantitative PCR Quantitative PCR (qPCR) amplifications were performed to measure the bacterial load (number of bacterial cells normalized by number of human cells) by using primers targeting the single-copy housekeeping bacterial gene FusA and the human b-actin gene (see Table E3 in this article's Online Repository at www.jacionline.org).
Determination of SIgA concentrations in stool samples
A commercially available ELISA kit was used for determination of total SIgA concentrations in fecal samples (ImmuChrom ELISA kit; ImmuChrom GmbH, Heppenheim, Germany), according to the manufacturer's instructions.
Statistics
Statistical analyses were performed with R software, version 3.2.2, and GraphPad Prism 6 software (version 6.1f; GraphPad Software, San Diego, Calif), in which a P value of less than .05 was considered significant. For a more comprehensive description of the statistical methods, please see the Methods section in this article's Online Repository.
RESULTS
Proportion of fecal bacteria bound to IgA in relation to allergy development
Infants with allergic symptoms during the first 7 years of life had significantly lower proportions of IgA-coated fecal bacteria at 12 months of age than healthy children (Fig 2, A) , whereas similar proportions were observed at 1 month of age. A low proportion of IgA-coated fecal bacteria at 12 months of age also preceded development of asthma (Fig 2, B) but not ARC (see Fig E2 in this article's Online Repository at www.jacionline.org). Moreover, independent of allergy development, an overall decreasing proportion of fecal bacteria bound to IgA from 1 to 12 months of age was observed, likely reflecting a change from predominantly maternally breast milk-derived to child-derived IgA antibodies. 22, 43 FIG 1 . Schematic workflow of performed experiments. The proportion of the IgA1 or IgA2 gut microbiota in infants was analyzed by using flow cytometry-based sorting of fecal samples before 16S rDNA 454-pyrosequencing. In addition, total SIgA levels were estimated by using ELISAs, and bacterial density was measured with universal primers targeting the single-copy bacterial gene FusA.
The influence of possible confounding factors was also evaluated. However, supplementation of the probiotic bacterium L reuteri, delivery mode, antibiotic treatments, and partial breastfeeding at 12 months of age did not affect the proportion of IgA-coated fecal bacteria (see Fig E3 in this article's Online Repository at www.jacionline.org).
Bacterial load, but not total SIgA levels, differ in healthy children and children with allergic manifestations Bacterial load and total SIgA levels in stool samples were measured to better understand detected differences in IgA proportions between healthy children and children with allergic manifestations. The bacterial load was higher at 12 months of age in children staying healthy than in those with allergic manifestations (Fig 3, A) but not significantly so for those with asthma (P 5 .11) and ARC (P 5 .61). A similar bacterial load was observed at 1 month of age in children staying healthy and having allergy (Fig 3, A) .
Total fecal SIgA levels were similar in healthy children and children with allergic manifestations (Fig 3, B) , asthma (P 5 .38 and P 5.71 for 1 and 12 months, respectively), and ARC (P 5.77 and P 5 .78 for 1 and 12 months, respectively). Fecal SIgA levels decreased significantly from 1 to 12 months of age in both groups (Fig 3, B) .
Bacterial targets of IgA responses in children with allergic manifestations and children staying healthy up to 7 years of age Bacterial 16S rDNA gene sequencing of IgA1 and IgA2 fractions was performed to assess early IgA responses in children staying healthy and children with allergic manifestations during the first 7 years of age. After quality filtering and removal of chimeric sequences, 190 samples with 633,378 high-quality sequence reads remained, with an average of 3,316 reads per sample and a mean length of 515 bp.
Although the analysis of the relative abundance of dominant bacterial families was generally similar between children with allergy and staying healthy (see Fig E4 in this article's Online Repository at www.jacionline.org), clear differences were observed on analyzing the bacterial targets of IgA responses, represented as the IgA index. IgA responses to the gut microbiota were demonstrated to differ between healthy children and children with allergic manifestations (Fig 4, A and B ) and asthmatic symptoms, particularly at 1 month but also 12 months of age (Fig 4, C and D) . At 1 month of age, the genus Faecalibacterium was mainly IgA free (IgA2) in children with allergic manifestations (including asthma but not ARC; see Fig E5 , A, in this article's Online Repository at www.jacionline.org). Moreover, the genera Parabacteroides and Anaerococcus were primarily not targeted by IgA in children with allergic manifestations when compared with healthy children.
At 12 months of age, the IgA responses of children with allergic manifestations were mainly not targeting the Bacteroides genus (Fig 4, B) , with similar findings observed for children with ARC (see Fig E5, B) . Regarding children with asthma symptoms, Escherichia/Shigella species was predominantly IgA free (Fig 4,  D) , whereas Lachnospiraceae incertae sedis, a Firmicutes phylum member, was predominantly IgA bound in children with allergic symptoms when compared with healthy children (Fig 4, B) . Furthermore, the genera Roseburia and Erysipelotrichaceae incertae sedis were generally IgA targeted in healthy children but not in children with allergic manifestations during (15) 60 (12) . 66 60 (6) 1.00
*The x 2 test was used to detect potential differences in frequencies between groups, except when the expected frequency for any cell was less than 5, in which case the Fisher exact test was used.
the first 7 years of life. In contrast, decreased IgA responses to the Veillonella genus were observed in healthy children. Possible differences in bacterial diversity in children with allergy and those staying healthy were also of interest. Thus Shannon indices for the IgA1 and IgA2 fractions were calculated. No differences, either at the genus (see Fig E6 in this article's Online Repository at www.jacionline.org) or phylum (see Fig E7, A and B, in this article's Online Repository at www. jacionline.org) level, were found in relation to allergy development, except that asthmatic children had increased diversity at 12 months among IgA-coated Bacteroidetes and Proteobacteria (see Fig E7, C) but not in the IgA-free fraction (see Fig E7, D) . IgA responses to the gut microbiota at 1 and 12 months of age. Plots depict IgA responses (defined by IgA index, reflecting the ratio in IgA1 and IgA2 gut microbiota) to dominant genera (>1% of total) of the gut microbiota at 1 month (n Healthy 5 27, n Allergic 5 19, and n Asthma 5 10) and 12 months (n Healthy 5 28, n Allergic 5 20, and n Asthma 5 10) of age when comparing healthy children and children with allergic (A and B) and asthmatic (C and D) symptoms. For a given genera, the value of the IgA index can range from positive values, reflecting genera found dominantly in the IgA1 fraction, to negative values (genera found dominantly in the IgA2 fraction) as a measure of the degree of mucosal immune responsiveness to the microbiota. The LEfSe algorithm, emphasizing both statistical and biological relevance, was used for biomarker discovery. The threshold for the logarithmic discriminant analysis (LDA) score was 2. Means with SEs are indicated. *P < .05 and **P < .01.
IgA recognition patterns of gut microbiota differ between healthy and allergic children
A PCA based on the calculated IgA indices was used to evaluate differences in IgA responses to the gut microbiota between healthy children and children with allergic manifestations, including asthma. Interestingly, the IgA recognition patterns differed already at 1 month of age when comparing healthy children and children with allergic (Fig 5, A) and asthmatic (Fig 5, C) symptoms but not ARC (see Fig E8, A, in this article's Online Repository at www.jacionline.org). Clear separation was observed at 12 months of age for healthy children and children with allergic disease (Fig 5, B) , asthma (Fig 5, D) , and ARC (see Fig E8, B) .
No effect of potential confounding factors (probiotic supplementation, delivery mode, antibiotic treatment, and partial breastfeeding at 12 months) on IgA recognition was observed (see Fig  E9 in this article's Online Repository at www.jacionline.org).
DISCUSSION
The data presented in the current study demonstrate that the first year of life represents an early critical period in which aberrant gut microbiota IgA responses are linked to the risk of asthma and allergic disease. SIgA functions as a first line of defense by interfering with the microbiota and thus protects the intestinal tissue from invasion and destruction by pathogenic and commensal bacteria. 18, 44 Thus intact production and function of IgA is a key mechanism to preserve intestinal health by directly influencing the properties of the microbiota and enhancing mucosal barrier function. 18 Furthermore, SIgA can also limit overgrowth of selected species, thus enabling an increased microbiota diversity. 18, 21 This can be particularly crucial during early childhood, when the microbiota plays a central role in immune modulation and during which microbial recognition by maternal and infant antibodies must be appropriately orchestrated for an optimal maturation of the immune system. [45] [46] [47] In line with this, low mucosal total IgA levels, [28] [29] [30] a reduced gut microbiota diversity in infancy, [8] [9] [10] [11] [12] [13] [14] [15] [16] and decreased seroreactivity to gut microbiota antigens 48 have been associated with allergy development. However, intestinal IgA responses to the infant gut microbiota have not previously been studied in relation to allergy development. To investigate this, we used a combination of flow cytometry and high-throughput deep sequencing to characterize the patterns of A B D C FIG 5 . IgA recognition patterns of the gut microbiota at 1 (left panels) and 12 (right panels) months. PCA based on the IgA index (reflecting the differences in IgA status, such as the ratio of IgA1 and IgA2) of the dominant genera (>1% of total) of the gut microbiota at 1 month (n Healthy 5 27, n Allergic 5 19, and n Asthma 5 9; A and C) and 12 months (n Healthy 5 27, n Allergic 5 19, and n Asthma 5 10; B and D) of age when comparing healthy children with children having allergic manifestations (Fig 5, A and B) or with children having asthmatic symptoms (Fig 5, C and D) .
bacterial recognition by IgA in stool samples collected at 1 and 12 months of age from children staying healthy or having allergic symptoms up to 7 years of age.
Interestingly, development of allergic disease, particularly asthma, during childhood was associated with a reduced proportion of IgA bound to fecal bacteria at 12 months of age. To better understand these differences, we sought to investigate whether the bacterial load and total fecal IgA levels might be of any influence. The results showed that lower proportions of IgA-coated fecal bacteria among children with allergic manifestations were independent of total fecal SIgA levels that were relatively similar to those of healthy children, especially at 12 months of age. Moreover, the decreased proportions of IgA-coated bacteria in allergic children are probably not due to lower IgA antibody/ bacteria ratios because bacterial densities were actually lower in children with allergies. Thus in addition to the lower bacterial diversity detected in other studies, [8] [9] [10] [11] [12] [13] [14] [15] [16] allergic children seem to be exposed to lower microbial densities in the gut. These 2 factors could lead to decreased stimulation of the immune system through Toll-like receptors, 19 affecting the production and microbial recognition patterns of IgA and leading to a lower proportion of IgA coating in allergic than healthy children. It would be interesting to further investigate the role of factors influencing IgA production, such as vitamin A-derived retinoic acid, TGF-b, IL-10, B cell-activating factor of the TNF family, and a proliferation-inducing ligand, 49 in the aberrant IgA responses in children with allergy in future studies. Because we previously found that a low gut microbiota diversity in infancy was mainly related to asthma, but not ARC, development at school age, 16 we aimed to determine the importance of IgA responses to the gut microbiota, particularly for asthma development. Speculatively, the association with asthma could be due to the fact that viral lower respiratory tract infections have been linked to asthma development among atopic children. 1, 50, 51 Thus low IgA responses to the microbiota might result in a reduced mucosal barrier function. This could cause increased susceptibility to airway viral infections, leading to amplification of T H 2 responses and subsequent asthma development. 1, 50, 51 Previous studies in adults have determined that IgA might be more reactive against disease-driving bacteria, 44, [52] [53] [54] which is in line with the theory that the immune system can distinguish between pathogens and commensals through sensing pathogenassociated behaviors, including adherence to the intestinal epithelium and tissue invasion. 53, 54 Also, SIgA can enable an increased microbiota diversity by limiting overgrowth of selected species. 18, 21 In the current study we observed that IgA recognition patterns differed between healthy children and children with allergic symptoms, including asthmatic disease and ARC, with clearly divergent IgA index patterns already at 1 month of age. Because the IgA antibodies at 1 month of age in exclusively breast-fed infants are predominantly maternally derived, 22 ,43 the divergent responses observed at this time suggest that immunologic interactions between mother and offspring influence allergy development, which is in line with previous studies. [45] [46] [47] For example, breast milk-derived SIgA had a large effect on microbial colonization in neonatal mice and was crucial for healthy intestinal epithelial barrier function and immune homeostasis in the offspring. 25 Interestingly, the gut commensals Faecalibacterium and Bacteroides were mainly IgA free at 1 and 12 months of age in children with allergic manifestations but were predominantly IgA coated in healthy children, especially at 12 months. These 2 genera are important human gut symbionts involved in production of butyrate, an end product of colonic fermentation that is important in maintaining a healthy gut. [55] [56] [57] Furthermore, decreased diversity of the Bacteroidetes phylum in infant stool samples has been linked to delivery by means of cesarean section 4, 58 and allergy development. 4, 12 Other commensals that seem to be ignored by IgA recognition in children with allergic symptoms were Parabacteroides at 1 month of age and Roseburia at 12 months of age. The Parabacteroides species distasonis has been shown to reduce inflammatory responses in murine models with chronic colitis, 59 whereas Roseburia is another well-known butyrate producer, 60 which was reduced in patients with ulcerative colitis. 61 In all, decreased coating of these commensals might reflect lower stimulation of the mucosal immune system in infants with allergic diseases.
The Erysipelotrichaceae family is considered highly immunogenic and seems important in inflammation-related disorders of the gastrointestinal tract because they are enriched in patients with colorectal cancer. 62 , 63 Palm et al 54 found that a member of the Erysipelotrichaceae was highly coated by IgA in specific pathogen-free mice relative to other members of the gut microbiota, proposing its role as a colitogenic bacteria. Furthermore, deregulation of T cells in mice affecting the selection of IgA plasma cells caused gut dysbiosis, including increased abundance of Erysipelotrichaceae, which are known to induce immune hyperactivation. 64 Escherichia and Shigella genera are Proteobacteria proposed to express highly proinflammatory hexa-acylated endotoxin production and were enriched in adult asthmatic patients, triggering airway inflammation. 65 Moreover, high abundance of fecal Escherichia coli was associated with development of IgE-associated eczema within the first year of life. 66 Because allergy and asthma development were associated with reduced IgA responses to the Erysipelotrichaceae and the Escherichia/Shigella genus, respectively, at 12 months of age, this might suggest an impaired mucosal immune exclusion of this genus in children with allergic disease, possibly leading to proinflammatory responses enhancing disease susceptibility.
In contrast, allergy development was associated with increased IgA responses at 12 months of age to Lachnospiraceae, grampositive barrier associated microbes that colonize the inner mucus layer, staying in close contact with host mucosa. 67, 68 Furthermore, excessive growth of species belonging to Lachnospiracea in mice with impaired IgA responses reduces Firmicutes diversity. 21 Thus the increased IgA coating of these bacteria in children with allergies might be an indication of an altered mucosal barrier function.
Factors that might influence the development of the intestinal microbiota and mucosal immune system include mode of delivery, exposure to antibiotics, partial breast-feeding at 12 months of age, and probiotic supplementation.
14,23,58,69,70 These confounding factors seem not to have influence in our study population because the discovered differences are driven by health status. However, larger studies are required to further investigate and confirm the role of these factors. Also, it needs to be determined whether our findings can be replicated in cohorts of other geographic origins and with a different family history of allergic disease.
In conclusion, our work suggests that studies of IgA responses to gut microbiota during infancy could be used to determine the normal development of mucosal immunity and establishment of a J ALLERGY CLIN IMMUNOL VOLUME 139, NUMBER 3 healthy symbiosis with gut microbes and how maternal immunity affects these processes. Early characterization of IgA coating patterns might represent a novel way to identify infants with increased risk of asthma and allergic disease, although this needs to be confirmed in larger cohorts. Furthermore, interventions enhancing infant mucosal barrier function might represent efficacious preventive strategies required to combat the asthma and allergy epidemic.
METHODS
Study design
The infants included in this study were part of a larger randomized doubleblind trial in southeastern Sweden between 2001 and 2005 evaluating the potential allergy prevention effect of probiotic L reuteri ATCC 55730 until 2 E1 and 7 E2 years of age. Among the 188 infants completing the original study, infant stool samples collected at 1 and 12 months of life in 20 children with allergy (Table E1 ) and 28 children staying healthy up to 7 years of age (Table E2) were randomly selected for this study. Ten of the allergic children had asthma. Other allergic diseases included eczema (n 5 9 at 7 years of age and n 5 17 at 2 years of age; no infants had eczema before 1 month of age), ARC (n 5 10), and allergic urticaria (n 5 1), with symptoms defined as described in detail previously.
E1,E2 The samples were immediately frozen at 2208C after collection and later stored at 2708C until use.
There were no differences regarding potential confounders, such as sex, mode of delivery, birth order, maternal atopy, breast-feeding, antibiotics, and probiotic supplementation, between the infants who did or did not experience allergic manifestations. All included infants were exclusively breast-fed for at least 1 month, and no infant received antibiotics before 1 month of age. E3 Informed consent was obtained from both parents before inclusion.
Sample labeling and flow cytometry protocol
Stool samples were suspended in sterile saline solution (autoclaved H 2 O; NaCl Sodium Chloride 99.5% PA-ACS-ISO; Panreac; reference 131689.1211) with 5% BSA (Sigma-Aldrich; reference A7030-100gr) to prevent nonspecific antibody binding. After short sonication, the samples were stained with goat anti-mouse IgA labeled with FITC (Invitrogen; reference M31001) or with goat anti-human IgA labeled with FITC (Invitrogen; reference H14001), according to the manufacturer's instructions. Anti-mouse IgA was used as an isotype control, determining the fluorescence intensity corresponding to unspecific binding (Fig E1) .
Sorting of the bacterial cells according to whether they were IgA coated (IgA1) or IgA noncoated (IgA2) was performed by using the MoFlo XDP Cell Sorter (Beckman Coulter), with a blue laser (488 nm; power of 200 mW) and red diode laser (635 nm; power of 25 mW) as a light source. The lasers were aligned by using Flow-Check (10 mm) and Flow-Set (3 mm) spheres. Bacterial cell separation was performed according to their fluorescence and forward scatter, reflecting IgA coating and cell size, respectively, according to the protocol by Simon-Soro et al. E4 
DNA extraction
DNA from sorted fecal bacteria, both IgA1 and IgA2, was isolated by using the MasterPure complete DNA and RNA Purification Kit (Epicentre Biotechnologies, Madison, Wis), according to the manufacturer's instructions, with a previous glass bead beating (0.17 mm in diameter) and an additional enzymatic lysis step with lysozyme (20 mg/mL, 378C, 30 minutes; Thermomixer comfort, Eppendorf). DNA was finally purified by using isopropanol/ ethanol extractions, as previously reported, E5 and the concentration and purity were measured by calculating A260/280 ratios with the NanoDrop 1000 Spectrophotometer (Thermo Fisher Scientific, Waltham, Mass).
16S rDNA gene amplification and sequencing
DNA from 192 samples in total was used for PCR amplification and pyrosequencing to describe the bacterial composition of the sorted populations. A region of approximately 650 bp of the 16S rDNA gene was amplified by using the universal bacterial degenerate primers 357F-CCTACGGGAGG-CAGCAG and 926R-CCGTCAATTCMTTTRAGT, E6 which encompass the hypervariable regions V3 to V5 of the gene. This was performed by using the high-fidelity AB-Gene DNA polymerase (Thermo Scientific) with an annealing temperature of 528C and 20 cycles to minimize amplification biases. E7 A secondary amplification (25 cycles, annealing temperature of 528C) was performed by using the purified PCR product as a template. E8 The primers in this step were modified to contain the pyrosequencing adaptors A and B linked to an 8-bp barcode specific to each sample. Barcodes were different in at least 3 nucleotides from each other to avoid errors in sample assignments.
The purification of PCR products was performed with NucleoFast 96 PCR filter plates (Macherey-Nagel, D€ uren, Germany), and the final concentration of the DNA per sample was measured by PicoGreen fluorescence (454 Life Science, Roche, Brandford, Conn) in a QuantiFlour Fluorometer from Promega Biosystems (model no. E6090; Promega, Sunnyvale, Calif). The PCR products were mixed in equimolar amounts, and pyrosequencing was performed from the forward primer end by using the 454 GS-FLX Pyrosequencer with Titanium chemistry (Roche, Basel, Switzerland) at the Center for Public Health Research (Valencia, Spain). One eighth of a plate was used for each pool of 20 to 25 samples.
Sequence processing and taxonomic classification
The resulting 16S rDNA read ends were trimmed in 10-bp sliding windows, with an average value of 20 or greater, by using the Galaxy tool E9 because quality has been shown to dramatically decrease toward the end of the sequences. E10 Only reads longer than 250 bp were considered, as well as those without mismatches in the primer region. The sequences were assigned to each sample by using the 8 bp barcode through the RDP pipeline, E11 version 11.3, and chimeric sequences were filtered out by using UCHIME.
E12
Taxonomic assignment was performed with the RDP classifier, E11 in which the reads were assigned a phylum, class, family, and genus, and phylogenetic ranks were allocated when scores exceeded the 0.8 confidence threshold. a Diversity analysis (Shannon indices) based on a randomly selected 700 reads per sample was used to estimate the samples' diversity at the gene and phylum levels. Here the sequences with greater than 97% identity and 90% sequence alignment length were considered to correspond to the same operational taxonomic units, thus representing a group of reads presumably belonging to the same species.
E13
For analyzing IgA coating patterns, the threshold used for including the genera was 1% or greater in relative abundance in either the IgA1 or IgA2 fractions. Furthermore, a pseudocount that was equal to 0.001 was added to every genera dedicated in both the IgA1 and IgA2 fractions, thus avoiding the fractions with a value of zero. The abundance proportions of a given genera were log-transformed before calculating the ratio between the IgA1 and IgA2 fractions, resulting in the IgA index. E14 Thus this score was based on proportional representation for every given genus within the IgA1 (positive IgA index values) and IgA2 fractions (negative IgA index values), reflecting the degree of mucosal immune responsiveness to the microbiota. LEfSe E15 was then used for high-dimensional biomarker discovery, comparing the IgA indices between healthy infants and infants with allergic manifestations. The used algorithm controls for the large number of statistical comparisons.
PCA is a statistical tool used to emphasize variation and bring out strong patterns in a data set. This analysis was performed with the R software ade4 package, E16 which is using a PCA constrained to Euclidean metric for multivariate data analysis and graphic display, in which samples with similar IgA index values appear closer to each other in the 2-dimensional space.
Bacterial load analysis with qPCR qPCR amplification and detection were performed to measure the bacterial load per human cell by using primers targeting the single-copy housekeeping gene FusA, which is present in bacterial cells. E17 Single-copy cellular sequence b-actin was used as a quality control for isolated genomic DNA (Table E3) . Amplifications were performed in duplicates on a LightCycler 480 Real-Time PCR System (Roche Technologies) by using an annealing temperature of 628C. Each reaction mixture of 10 mL was composed of SYBR Green PCR Master Mix (Roche), 0.5 mL of the specific primer (concentration 10 mmol/L), and 2 mL of DNA template. The bacterial cell numbers in each sample were calculated by comparing the cycle threshold values obtained from those in standard curves. These were generated by using serial 10-fold dilutions of DNA extracted from 10 million bacteria from infant stool samples and from 5 million human umbilical vein endothelial cells (Advancell, Barcelona, Spain) E18 quantified and sorted by using flow cytometry.
Determination of SIgA concentrations in stool samples
A commercially available ELISA kit was used for determination of total SIgA concentrations in fecal samples (ImmuChrom ELISA kit, ImmuChrom GmbH). One milliliter of a fecal suspension (100 mg of stool sample in 5 mL of wash buffer) was centrifuged for 10 minutes at 10,000g, and the resulting supernatant (diluted 1:250 with wash buffer) was used in the assay. Samples were additionally diluted 1:10 and 1:5 for samples collected at 1 and 12 months of age, respectively, because of high antibody concentrations. The manufacturer's guidelines were followed. The plates were read at 450 nm, with 620 nm as the reference wavelength, on the Infinite F200 plate reader (Tecan Trading AG, M€ annedorf, Switzerland). All samples were analyzed in duplicates, and the detection limit was 3.1 ng/mL.
Statistics
Statistical analyses were performed in R version 3.2.2 and GraphPad Prism 6 (Version 6.1f; GraphPad Software) software, in which a P value of less than .05 was considered significant. The x 2 test was used to detect the potential influence of confounding factors between the groups. The Fisher exact test was performed when expected frequency for any cell was less than 5. a Diversity analyses were performed by using the statistical software R with the vegan package. E19 Bar plots are presented as mean values with error bars representing SEMs, whereas the scatter plots demonstrate medians with interquartile ranges. Specific statistical tests are noted in figure legends. For the PCA analysis, the DMwR package of R was used for removing 2 outliers: sample codes 5 (Table E1 ) and 20 (Table E2 ). This was done according to the local outlier factor, an algorithm that identifies density-based outliers by comparing local outlier factor values. E20 FIG E1. Scatter plots presenting how the gating strategy was performed. A, A blank control (unlabeled bacterial cells) was used to determine the threshold for autofluorescence. B, Anti-mouse IgA antibodies were used as an isotype control, determining the fluorescence intensity corresponding to unspecific binding (indicated as area R2 in the plot). Green fluorescence greater than the isotype control threshold was considered indicative of true IgA coating (indicated as area R3 in the plot). C, An example of a scatter plot from an anti-human IgA sample that was gated according to the controls above. In this particular patient sample, which was collected at 12 months of age, most bacteria appear as IgA-coated cells. (Fig E4, A and B) and 12 months (Fig E4, C and D Bacterial phyla diversity of IgA-coated and noncoated bacteria in stool samples of healthy children and children with allergic/asthmatic symptoms. Shannon index, based on a randomly selected 700 reads per sample, was used to estimate the samples' diversity of the most dominant phyla: Actinobacteria, Bacteroidetes, Firmicutes and Proteobacteria. Samples with lower amounts of reads were excluded from the analysis. A and B, Phylum diversity of IgA-coated (IgA1) and IgA-noncoated (IgA2) fractions, respectively, at different time points, from infants who did (A) or did not (H) have allergic manifestations during the first 7 years of life. C and D, Shannon diversity index for the most dominant phyla in IgA1 and IgA2 fractions, respectively, from infants who did (As) or did not (H) have asthmatic manifestations during the first 7 years of life. Data are presented as medians and interquartile ranges. *P < .05, **P < .01, ***P < .001, Mann-Whitney U test. A, Allergic; As, asthmatic disease; H, healthy; IgA1, IgA-coated bacterial fraction; IgA2, IgA-noncoated bacterial fraction. Fig E9, B) . C and D, IgA recognition patterns in children that were vaginally delivered or delivered by means of cesarean section at 1 month of age (n Vaginally 5 38 and n C-section 5 8; Fig E9, C) and 12 months of age (n Vaginally 5 40 and n C-section 5 8; Fig E9, D) . E, Patterns of IgA recognition for the children at 12 months of age who were untreated (n 5 31) and treated (n 5 17) with antibiotics during their first year of life. F, IgA recognition patterns toward microbiota in children who were not breast-fed (n 5 36) or who were still partially breast-fed (n 5 12) at 12 months of age. 
